Defence's Corporate Updates, Arranges Financing
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) announces corporate updates and financing plans. Key points include:
1. Sebastien Plouffe returns as CEO, replacing Kwin Grauer.
2. New board appointments: Dr. Philippe Lefrançois and Mr. Arnab De.
3. Dr. Moutih Rafei steps down from the board but remains CSO.
4. Joseph Meagher leaves the board but stays as CFO during transition to Arnab De.
5. 200,000 stock options granted to new directors at $0.60 per share.
6. Non-brokered private placement announced for up to $3 million at $0.50 per unit, with each unit including one common share and half a warrant.
7. Proceeds to be used for advancing preclinical and clinical programs, and working capital.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) annuncia aggiornamenti aziendali e piani di finanziamento. I punti chiave includono:
1. Sebastien Plouffe torna come CEO, sostituendo Kwin Grauer.
2. Nuove nomine nel consiglio: Dr. Philippe Lefrançois e Mr. Arnab De.
3. Il Dr. Moutih Rafei si dimette dal consiglio ma rimane CSO.
4. Joseph Meagher lascia il consiglio ma rimane CFO durante la transizione verso Arnab De.
5. 200.000 opzioni su azioni concesse ai nuovi direttori a $0,60 per azione.
6. È stato annunciato un collocamento privato non assistito fino a $3 milioni a $0,50 per unità, con ogni unità che include un'azione ordinaria e metà di un warrant.
7. I proventi saranno utilizzati per il progresso dei programmi preclinici e clinici, e per il capitale circolante.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) anuncia actualizaciones corporativas y planes de financiamiento. Los puntos clave incluyen:
1. Sebastien Plouffe regresa como CEO, reemplazando a Kwin Grauer.
2. Nuevas designaciones en la junta: Dr. Philippe Lefrançois y Mr. Arnab De.
3. Dr. Moutih Rafei renuncia a la junta pero permanece como CSO.
4. Joseph Meagher deja la junta pero se queda como CFO durante la transición a Arnab De.
5. Se conceden 200,000 opciones sobre acciones a los nuevos directores a $0.60 por acción.
6. Se anuncia una colocación privada no mediada por hasta $3 millones a $0.50 por unidad, con cada unidad que incluye una acción ordinaria y medio warrant.
7. Los ingresos se utilizarán para avanzar en programas preclínicos y clínicos, así como para el capital de trabajo.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)는 기업 업데이트 및 금융 계획을 발표합니다. 주요 내용은 다음과 같습니다:
1. Sebastien Plouffe가 CEO로 복귀하고 Kwin Grauer를 교체합니다.
2. 새로운 이사: Dr. Philippe Lefrançois와 Mr. Arnab De가 임명됩니다.
3. Dr. Moutih Rafei는 이사회에서 물러나지만 CSO를 유지합니다.
4. Joseph Meagher는 이사회를 떠나지만 Arnab De로의 전환 기간동안 CFO로 남습니다.
5. 새로운 이사를 위해 $0.60의 주가로 200,000개의 스톡 옵션이 부여됩니다.
6. $3백만까지의 비중개 프라이빗 플래시 서비스가 발표되었으며, 각 유닛에는 한 개의 보통주와 반 개의 보증서가 포함됩니다.
7. 수익금은 전임상 및 임상 프로그램의 진행과 운영 자금으로 사용될 예정입니다.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) annonce des mises à jour d'entreprise et des plans de financement. Les points clés incluent :
1. Sebastien Plouffe revient en tant que PDG, remplaçant Kwin Grauer.
2. Nouvelles nominations au conseil : Dr. Philippe Lefrançois et Mr. Arnab De.
3. Dr. Moutih Rafei démissionne du conseil mais reste CSO.
4. Joseph Meagher quitte le conseil mais reste CFO durant la transition vers Arnab De.
5. 200 000 options d'achat d'actions accordées aux nouveaux directeurs à 0,60 $ par action.
6. Une placement privé sans intermédiaire annoncé pour un maximum de 3 millions $ à 0,50 $ par unité, chaque unité incluant une action ordinaire et une demi-option.
7. Les recettes seront utilisées pour faire progresser les programmes précliniques et cliniques, ainsi que pour le fonds de roulement.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) gibt Unternehmensupdates und Finanzierungspläne bekannt. Wichtige Punkte sind:
1. Sebastien Plouffe kehrt als CEO zurück und ersetzt Kwin Grauer.
2. Neue Vorstandsmitglieder: Dr. Philippe Lefrançois und Mr. Arnab De.
3. Dr. Moutih Rafei tritt aus dem Vorstand zurück, bleibt jedoch CSO.
4. Joseph Meagher verlässt den Vorstand, bleibt aber während des Übergangs zu Arnab De CFO.
5. 200.000 Aktienoptionen werden den neuen Direktoren zu einem Preis von 0,60 $ pro Aktie gewährt.
6. Es wurde ein nicht vermittelte Privatplatzierung für bis zu 3 Millionen $ zu 0,50 $ pro Einheit angekündigt, wobei jede Einheit eine Stammaktie und eine halbe Option umfasst.
7. Die Erlöse sollen zur Weiterentwicklung der präklinischen und klinischen Programme sowie für das Betriebskapital verwendet werden.
- Sebastien Plouffe, company founder, returns as CEO to advance programs and negotiate potential business deals
- Appointment of Dr. Philippe Lefrançois, an expert in skin cancer and familiar with Defence's Accum® platform technology
- Addition of Arnab De, an experienced financial executive, to the board and as incoming CFO
- Non-brokered private placement of up to $3 million announced to fund preclinical and clinical programs
- Multiple changes in leadership positions may lead to temporary instability
- Dilution of existing shareholders due to the new private placement offering
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give a corporate update and to announce a financing.
The Company wishes to announce that Mr. Sebastien Plouffe, Defence's Founder and Director, is stepping back-in as the Chief Executive Officer, effective immediately. Mr. Plouffe involvement and guidance at this important stage of the Company is to efficiently advance the programs, to negotiate potential business deals and to secure financing into the Company. Mr. Kwin Grauer, interim CEO during Mr. Plouffe's absence, is stepping down of his role and of the board of directors. The Company wishes to thank Mr. Grauer for his involvement and efforts to help Defence's to grow.
The Company would also like to announce two new nominations to its board of directors: Dr. Philippe Lefrançois and Mr. Arnab De, in replacement of Dr. Moutih Rafei who's stepping down from the board of directors but remains the CSO and Mr. Joseph Meagher who's stepping down from the board of directors but remains the CFO during the transition with the incoming CFO Mr. Arnab De. The Company is thanking Dr. Rafei and Mr. Meagher for their valuable contributions to the board of directors.
Dr. Philippe Lefrançois is the Director of Research in the Division of Dermatology at McGill University. He is an Assistant Professor of Medicine, of Pharmacology & Therapeutics, and of Surgery. He is a full-time staff dermatologist at the Jewish General Hospital where he is actively involved in multidisciplinary skin cancer clinics and tumor boards. He is an investigator at the Lady Davis Institute where he established a broad skin cancer biobank and a skin cancer translational genomics laboratory. He leads the Terry Fox Research Institute - Marathon of Hope Cancer Centre Network initiatives on BCC and SCC. He is a member of the Réseau Recherche Cancer - Québec, and Québec Cancer Consortium. His translational activities include collaborations with biotechs to bring novel cancer therapeutics and diagnostics to pre-clinical and phase I studies. Dr. Lefrançois holds a Ph.D. from Yale University, and a M.D. from Université de Montréal. He completed his dermatology residency at McGill. His work on skin cancers has been recognized by the CDA and the AAD.
Mr. Arnab De, CPA, CGMA, CMA, MBA, is a strong seasoned executive with more than 20 years of experience in financial management, financial planning, business optimization and strategy development. He is the principal of Resurgent Montreal Inc., a financial management consulting firm. Prior to that he worked for 19 years in the Tata Group holding CFO positions in JCAPCPL (a 50:50 JV of Tata Steel with Nippon Steel) producing automotive steels and Tata Steel Minerals Canada Ltd., where he oversaw the DSO project from conception and managed an investment of +
"Dr. Philippe Lefrançois has previously worked with Defence's Accum® platform technology, having been involved in one of the ARM-XTM preclinical studies, and he strongly believes in its potential. He's also specialized in melanoma, which is a great advantage for Defence to have his advice and guidance prior to begin its Phase I clinical trial using AccuTOX® as an anti-cancer molecule in patients with melanoma (see July 8, 2024, press release where Defence's announced it received the No Objection Letter from Health Canada for Phase I trial). Mr. Arnab De is a strong addition to the Company for his experience in the financial planning, strategy and regulatory affairs", said Mr. Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.
The Company has granted a total of 200,000 incentive stock options split equally to the two new directors: 100,000 incentive stock options to Dr. Lefrançois and 100,000 incentive stock options to Mr. De, in accordance with the terms and conditions of Defence's stock option plan, subject to any regulatory approval. Each stock option vests immediately and is exercisable at a price of
The Company announces a non-brokered private placement of up to
The Company intends to use the net proceeds to advance its preclinical and clinical programs, and for general working capital. The Company may pay a finder's fee in connection with the offering in accordance with the policies of the CSE. The securities issued in connection with the offering will be subject to a statutory hold period of four months and one day following the closing date in accordance with the CSE.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224803
FAQ
What is the stock symbol for Defence Therapeutics Inc.?
Who is the new CEO of Defence Therapeutics (DTCFF) as of September 27, 2024?
What is the price per unit in Defence Therapeutics' (DTCFF) new private placement offering?
How much funding is Defence Therapeutics (DTCFF) aiming to raise through its private placement?
